Xianju Pharmaceutical Receives US FDA Filing Acceptance for Progesterone Vaginal Tablets

Stock News

Sep 01

Zhejiang Xianju Pharmaceutical Co.,Ltd. (002332.SZ) has announced that its Abbreviated New Drug Application (ANDA) for progesterone vaginal tablets has been formally accepted for review by the U.S. Food and Drug Administration (FDA).

The company confirmed it recently received the official notification from the US regulator regarding the acceptance of its registration filing.

The progesterone vaginal tablet is indicated for luteal phase support in assisted reproductive technology (ART), aiming to supplement luteal function to facilitate embryo implantation and support early pregnancy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1122293255"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1122293255\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1122293255?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-01 19:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122293255","market":"us","top_or_hot":-1,"title":"Xianju Pharmaceutical Receives US FDA Filing Acceptance for Progesterone Vaginal Tablets","media":"Stock News","content":"<p><b>Zhejiang Xianju Pharmaceutical Co.,Ltd.</b> (002332.SZ) has announced that its Abbreviated New Drug Application (ANDA) for progesterone vaginal tablets has been formally accepted for review by the U.S. Food and Drug Administration (FDA).<br><br>The company confirmed it recently received the official notification from the US regulator regarding the acceptance of its registration filing.<br><br>The progesterone vaginal tablet is indicated for luteal phase support in assisted reproductive technology (ART), aiming to supplement luteal function to facilitate embryo implantation and support early pregnancy.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xianju Pharmaceutical Receives US FDA Filing Acceptance for Progesterone Vaginal Tablets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXianju Pharmaceutical Receives US FDA Filing Acceptance for Progesterone Vaginal Tablets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-01 19:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Zhejiang Xianju Pharmaceutical Co.,Ltd.</b> (002332.SZ) has announced that its Abbreviated New Drug Application (ANDA) for progesterone vaginal tablets has been formally accepted for review by the U.S. Food and Drug Administration (FDA).<br><br>The company confirmed it recently received the official notification from the US regulator regarding the acceptance of its registration filing.<br><br>The progesterone vaginal tablet is indicated for luteal phase support in assisted reproductive technology (ART), aiming to supplement luteal function to facilitate embryo implantation and support early pregnancy.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"002332","symbol_name":"仙琚制药","start_time":0,"source_url":"","article_id":"1122293255","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122293255","pubTimestamp":1788260669,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zhejiang Xianju Pharmaceutical Co.,Ltd. (002332.SZ) has announced that its Abbreviated New Drug Application (ANDA) for progesterone vaginal tablets has been formally accepted for review by the U.S....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"002332":"仙琚制药","BK0239":"医药制造","BK0028":"国家队","SG9999014674.SGD":"Nikko AM All China Equity A SGD","BK4585":"ETF&股票定投概念","BK4588":"碎股","LABU":"三倍做多标普生物-Direxion"},"translate_title":"仙居制药黄体酮阴道片获美国FDA备案受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1,"002332":1},"content_text":"Zhejiang Xianju Pharmaceutical Co.,Ltd. (002332.SZ) has announced that its Abbreviated New Drug Application (ANDA) for progesterone vaginal tablets has been formally accepted for review by the U.S. Food and Drug Administration (FDA).The company confirmed it recently received the official notification from the US regulator regarding the acceptance of its registration filing.The progesterone vaginal tablet is indicated for luteal phase support in assisted reproductive technology (ART), aiming to supplement luteal function to facilitate embryo implantation and support early pregnancy.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}